Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab vs Corticosteroids for Immune Checkpoint Inhibitor Colitis in Skin Cancer
NCT04305145Phase 2Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Aug 2020
- Primary completion
- Jun 2030
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised trial of infliximab in Drug-induced colitis (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Proportion of patients with Steroid-Free Colitis at 7 weeks. Started Aug 2020; status: active, not recruiting.
02
Drugs
infliximab
03
Conditions
Drug-induced colitis
Beyond the preview
Go deeper on NCT04305145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04305145.